« Back
Home /
Belnacasan (VX-765)

Belnacasan (VX-765)

Item no.	S2228-50
Manufacturer	Selleckchem
CASRN	273404-37-8
Amount	50 mg
Quantity options	10 mg 1 g 10 g 10 mM/1 mL 200 mg 50 mg 5 g
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Smiles	CCOC1C(CC(=O)O1)NC(=O)C2CCCN2C(=O)C(C(C)(C)C)NC(=O)C3=CC(=C(C=C3)N)Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Caspase-1,Caspase
Available
Storage Conditions	2 years -80 in solvent
Molecular Weight	509
Administration	Administered via p.o.
Animal Models	Collagen-induced arthritis mouse model.
Clinical Trials	VX-765 is currently in Phase II clinical trials in patients with treatment-resistant partial epilepsy.
Dosages	<=200 mg/kg
Formulation	VX-765 is dissolved in 25% Cremophor EL.
IC50	0.8 nM (Ki) [1], 0.8 nM (Ki) [1], 0.8 nM (Ki) [1], 0.8 nM (Ki) [1], 0.8 nM (Ki) [1], 0.8 nM (Ki) [1]
In vitro	VX-765 is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and caspase-4 with Ki of 0.8 nM and less than 0.6 nM, respectively. And VRT-043198 also inhibits IL-1beta release from both PBMCs and whole blood with IC50 of 0.67 uM and 1.9 uM, respectively., [1]
In vivo	In collagen-induced arthritis mouse model, VX-765 (200 mg/kg) inhibits LPS-induced IL-1beta production by about 60%, and results in, a dose-dependent, statistically significant reduction in the inflammation scores and effective protection from joint changes., [1] In vivo, VX-765 blocks kindling epileptogenesis in rats by preventing IL-1beta increase in forebrain astrocytes without significant effect on afterdischarge duration., [2] In the mouse model of acute seizures, VX-765 (50 mg/kg-200 mg/kg) produces the anticonvulsant effect by delaying the time to onset of the first seizure and decreasing the number of seizures as well as their total duration by average 50% and 64%., [3] In adult rats with genetic absence epilepsy (GAERS), VX-765, after the 3rd drug injection, significantly reduces the cumulative duration and number of spike-and-wave discharges (SWDs) by 55% on average by selectively blocking IL-1beta biosynthesis., [4]
Kinase Assay	Protease Enzyme Assays, Enzyme inhibition is assayed by tracking of the rate of hydrolysis of an appropriate substrate labeled with either p-nitroaniline or aminomethyl coumarin (AMC) as follows: ICE/caspase-1, suc-YVAD-p-nitroanilide, caspase-4, Ac-WEHD-AMC, caspase-6, Ac-VEID-AMC, caspase-3, -7, -8, and -9, Ac-DEVD-AMC, and granzyme B, Ac-IEPD-AMC. Enzymes and substrates are incubated in a reaction buffer [10 mM Tris, pH 7.5, 0.1% (w/v) CHAPS, 1 mM dithiothreitol, and 5% (v/v) dimethyl sulfoxide] for 10 minutes at 37 C. Glycerol is added to the buffer at 8% (v/v) for caspase-3, -6, and -9 and granzyme B to improve stability of enzymes. The rate of substrate hydrolysis is monitored using a fluorometer.
Solubility (25C)	DMSO 102 mg/mL, Water <1 mg/mL, Ethanol 102 mg/mL
Information	Belnacasan (VX-765) is a potent and selective inhibitor of caspase-1 with Ki of 0.8 nM in a cell-free assay. Phase 2.
Chemical Name	(S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3, 3-dimethylbutanoyl)-N-((2R, 3S)-2-ethoxy-5-oxo-tetrahydrofuran-3-yl)pyrrolidine-2-carboxamide
Features	VX-765 is a potent and selective inhibitor of interleukin-converting enzyme/caspase-1.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S2228-50-datasheet.pdf

S2228-50-safety-datasheet.pdf